Literature DB >> 10074152

Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

J F Kaye1, A M Lever.   

Abstract

Retroviral RNA encapsidation is a highly selective process mediated through recognition by the viral Gag proteins of cis-acting RNA packaging signals in genomic RNA. This RNA species is also translated, producing the viral gag gene products. The relationship between these processes is poorly understood. Unlike that of human immunodeficiency virus type 1 (HIV-1), the dominant packaging signal of HIV-2 is upstream of the major splice donor and present in both unspliced and spliced viral RNAs, necessitating additional mechanisms for preferential packaging of unspliced genomic RNA. Encapsidation studies of a series of HIV-2-based vectors showed efficient packaging of viral genomes only if the unspliced, encapsidated RNA expressed full-length Gag protein, including functional nucleocapsid. We propose a novel encapsidation initiation mechanism, providing selectivity, in which unspliced HIV-2 RNA is captured in cis by the Gag protein. This has implications for the use of HIV-2 and other lentiviruses as vectors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074152      PMCID: PMC104062     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

Authors:  F Clavel; J M Orenstein
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

Authors:  A Aldovini; R A Young
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Autogenous regulation of RNA translation and packaging by Rous sarcoma virus Pr76gag.

Authors:  T S Sonstegard; P B Hackett
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

Authors:  R J Gorelick; S M Nigida; J W Bess; L O Arthur; L E Henderson; A Rein
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

6.  Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.

Authors:  J G Levin; P M Grimley; J M Ramseur; I K Berezesky
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

7.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants.

Authors:  T Koyama; F Harada; S Kawai
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector.

Authors:  M Poznansky; A Lever; L Bergeron; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions.

Authors:  A Lever; H Gottlinger; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

View more
  50 in total

Review 1.  Destiny of unspliced retroviral RNA: ribosome and/or virion?

Authors:  Melinda Butsch; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Translation is not required To generate virion precursor RNA in human immunodeficiency virus type 1-infected T cells.

Authors:  M Butsch; K Boris-Lawrie
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Splicing affects presentation of RNA dimerization signals in HIV-2 in vitro.

Authors:  Jean-Marc Lanchy; Quenna N Szafran; J Stephen Lodmell
Journal:  Nucleic Acids Res       Date:  2004-08-27       Impact factor: 16.971

4.  High frequency of genetic recombination is a common feature of primate lentivirus replication.

Authors:  Jianbo Chen; Douglas Powell; Wei-Shau Hu
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  Encapsidation determinants located downstream of the major splice donor in the maedi-visna virus leader region.

Authors:  Helga Bjarnadottir; Bjarki Gudmundsson; Janus Gudnason; Jon J Jonsson
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

6.  In vitro expression of the HIV-2 genomic RNA is controlled by three distinct internal ribosome entry segments that are regulated by the HIV protease and the Gag polyprotein.

Authors:  Emiliano P Ricci; Cécile H Herbreteau; Didier Decimo; Andreas Schaupp; Siddhartha A K Datta; Alan Rein; Jean-Luc Darlix; Théophile Ohlmann
Journal:  RNA       Date:  2008-05-21       Impact factor: 4.942

Review 7.  Diverse interactions of retroviral Gag proteins with RNAs.

Authors:  Alan Rein; Siddhartha A K Datta; Christopher P Jones; Karin Musier-Forsyth
Journal:  Trends Biochem Sci       Date:  2011-05-06       Impact factor: 13.807

8.  Accuracy estimation of foamy virus genome copying.

Authors:  Kathleen Gärtner; Tatiana Wiktorowicz; Jeonghae Park; Ayalew Mergia; Axel Rethwilm; Carsten Scheller
Journal:  Retrovirology       Date:  2009-04-06       Impact factor: 4.602

Review 9.  Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome.

Authors:  Cheryl Bolinger; Kathleen Boris-Lawrie
Journal:  Retrovirology       Date:  2009-01-24       Impact factor: 4.602

10.  A new type of IRES within gag coding region recruits three initiation complexes on HIV-2 genomic RNA.

Authors:  Laure Weill; Laurie James; Nathalie Ulryck; Nathalie Chamond; Cecile H Herbreteau; Theophile Ohlmann; Bruno Sargueil
Journal:  Nucleic Acids Res       Date:  2009-12-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.